文献速递生殖医学产科

癌症幸存者体外受精后的出生结局

Birth outcomes after in vitro fertilization among cancer survivors.
PubMed 文献 · Fertil Steril · 2026-01-29

这项回顾性队列研究分析了2004-2018年九个州135,274例单胎体外受精(IVF)出生,其中648例来自癌症患者(112例在癌症治疗前取卵即生育力保存,536例在癌症治疗后取卵)。与无癌症的IVF出生相比,生育力保存组的早产(13%)、低出生体重(10%)、小于胎龄儿(12%)和大于胎龄儿(10%)风险相似,但剖宫产更常见(55% vs. 44%-49%);癌症治疗后取卵组除大于胎龄儿风险较低外,其他不良出生结局风险与无癌症IVF出生相似。

要点

  • 癌症患者IVF后早产、低出生体重、小于胎龄儿风险与无癌症IVF患者相似。
  • 生育力保存组剖宫产率55%,高于无癌症IVF参照组的44%-49%。
  • 癌症治疗后取卵组大于胎龄儿风险低于无癌症IVF参照组。

核心结论

  • 除大于胎龄儿外,癌症与非癌症IVF指征的IVF出生在多种不良出生结局上风险相似。
  • 研究结果支持使用非癌症IVF背景下的证据为癌症患者/幸存者提供IVF后出生结局的咨询。

研究设计与样本

  • 回顾性队列研究,纳入2004-2018年九个州(加利福尼亚、科罗拉多、马萨诸塞、马里兰、密歇根、北卡罗来纳、新泽西、纽约、弗吉尼亚)的单胎IVF出生。
  • 共135,274例IVF出生,其中648例来自有癌症史并在癌症治疗前(生育力保存,n=112)或治疗后(n=536)取卵的患者。
  • 无癌症IVF参照组包括男性因素不孕(n=33,284例出生)、输卵管结扎(n=1,258例出生)和所有其他IVF指征(n=100,084例出生)。

主要发现

  • 生育力保存组早产13%、低出生体重10%、小于胎龄儿12%、大于胎龄儿10%,与无癌症IVF参照组相似,但剖宫产55%比参照组44%-49%更常见。
  • 癌症治疗后取卵组在调整种族、教育、婴儿性别和新鲜/冷冻胚胎状态后,妊娠期高血压6%、早产13%、低出生体重9%、小于胎龄儿9%和剖宫产53%与无癌症IVF出生不一致差异,但大于胎龄儿风险较低(8%)。
  • 癌症治疗后取卵组大于胎龄儿风险低于男性因素不孕组(10%,RR=0.69,95%CI=0.51-0.93)、输卵管结扎组(13%,RR=0.56,95%CI=0.40-0.78)和所有其他非癌症IVF指征组(10%,RR=0.71,95%CI=0.53-0.96)。

临床怎么用

  • 可为癌症患者/幸存者提供IVF后出生结局咨询时参考非癌症IVF人群的证据。
  • 应告知生育力保存患者剖宫产风险可能较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine if patients with cancer who retrieve oocytes for in vitro fertilization (IVF) before or after cancer treatment have an increased risk of adverse birth outcomes compared with other IVF patients without cancer in the United States. DESIGN: Retrospective cohort study. SUBJECTS: Singleton IVF births during 2004-2018 from women with and without a history of cancer in nine states (California, Colorado, Massachusetts, Maryland, Michigan, North Carolina, New Jersey, New York, and Virginia). EXPOSURE: Women with a cancer history before IVF who had oocyte retrieval before cancer treatment (fertility preservation) or after cancer treatment. MAIN OUTCOME MEASURES: Multivariable relative risks (RR) and 95% confidence intervals (CI) for gestational hypertension, low birthweight [LBW, <2,500 g], preterm birth [PTB, <37 weeks], small for gestational age (SGA), large for gestational age (LGA), and cesarean delivery. RESULTS: Among 135,274 IVF births, 648 were from patients with cancer who retrieved oocytes before (fertility preservation, n=112) or after (n=536) cancer treatment. The IVF births in patients with cancer were compared with noncancer IVF births, which had IVF indications of male factor infertility (n=33,284 births), tubal ligation (n=1,258 births), and all other IVF indications (n=100,084 births). Preterm birth (13%), LBW (10%), SGA (12%), and LGA (10%) in the fertility preservation group were similar to noncancer IVF referent groups, but cesarean section (55% vs. 44%-49%) was more common. In models adjusted for race, education, infant sex, and fresh/frozen embryo state, IVF births with oocyte retrieval after cancer treatment did not consistently differ from noncancer IVF births for gestational hypertension (6%), PTB (13%), LBW (9%), SGA (9%), and cesarean delivery (53%), but had lower risk of LGA (8%) compared with male factor infertility (10%, RR=0.69, 95% CI=0.51-0.93), tubal ligation (13%, RR=0.56, 95% CI=0.40-0.78), and all other noncancer IVF indications (10%, RR=0.71, 95% CI=0.53-0.96). CONCLUSION: With the exception of LGA, we found similar risks of several adverse birth outcomes among IVF births across cancer and noncancer indications for IVF. These findings support the use of evidence from noncancer IVF contexts for counseling of patients with cancer/survivors about birth outcomes after IVF.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Brookes J, Wardell AC, Anderson C, et al. Birth outcomes after in vitro fertilization among cancer survivors. Fertil Steril. 2026. PMID: 41619899. doi:10.1016/j.fertnstert.2026.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。